NCT03162185 is a Phase 4 clinical trial of Escitalopram in Healthy Controls, sponsored by Max Planck Institute for Human Cognitive and Brain Sciences.

Who is sponsoring NCT03162185?

NCT03162185 is sponsored by Max Planck Institute for Human Cognitive and Brain Sciences.

What drugs are being tested in NCT03162185?

Interventions in NCT03162185: Escitalopram, Placebo.

What condition does NCT03162185 study?

NCT03162185 studies Healthy Controls.

Is NCT03162185 still recruiting?

NCT03162185 is currently status unknown. Last updated 22 May 2017.

Last reviewed 2017-05-22 · How we verify

NCT03162185

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Serotonin and Motor Plasticity

Status unknown Phase 4 Last updated 22 May 2017

What this trial tests

Phase 4 trial testing Escitalopram in Healthy Controls in 60 participants. Status unknown.

Timeline

1 April 2017

Primary endpoint
30 November 2017

30 November 2017

Quick facts

Lead sponsor	Max Planck Institute for Human Cognitive and Brain Sciences
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	basic science
Enrollment	60
Start date	1 April 2017
Primary completion	30 November 2017
Estimated completion	30 November 2017
Sites	1 location across Germany

Drugs / interventions tested

Escitalopram (escitalopram) — full drug profile →
Placebo

Conditions studied

Healthy Controls — all drugs for Healthy Controls →

Sponsor

Max Planck Institute for Human Cognitive and Brain Sciences

Who can join

Adults 20 to 40, female only, with Healthy Controls. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

With this study, the investigators aim to test whether acute administration of selective serotonin reuptake inhibitors (SSRI) improves motor performance in a sequential motor learning task in comparison to placebo in healthy humans.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

One-week escitalopram intake alters the excitation-inhibition balance in the healthy female brain.
Zsido RG, Molloy EN, Cesnaite E, Zheleva G, et al · · 2022 · cited 15× · PMID 35064716 · DOI 10.1002/hbm.25760
Modulation of premotor cortex response to sequence motor learning during escitalopram intake.
Molloy EN, Mueller K, Beinhölzl N, Blöchl M, et al · · 2021 · cited 4× · PMID 33148103 · DOI 10.1177/0271678x20965161

Verify or expand the search:

Other trials of Escitalopram

Trials testing the same drug.

NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT07331987 — Efficacy and Safety of Probiotics for Anxiety Depression · NA · not yet recruiting
NCT06216535 — Escitalopram in Asthma Patients With Frequent Exacerbation · Phase 2 · recruiting
NCT06937476 — Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole · NA · active not recruiting
NCT05603104 — Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First- · Phase 3 · recruiting

Other recruiting trials for Healthy Controls

Currently open trials in the same condition.

NCT06732440 — Subthreshold Vestibular Stimulation as a Strategy for Rehabilitation · NA · recruiting
NCT07376915 — Acute Effect of Graded Motor Imagery on Ankle Rehabilitation: A Pilot Study · NA · recruiting
NCT07276087 — Physical and Psychosocial Parameters in Takayasu Arteritis and Behçet's Disease: A Comparative Study With Healthy Contro · recruiting
NCT06979154 — Pilot Study of Personalized Aperiodic Transcranial Alternating Current Stimulation in Antenatal Depression (PandA-tACS) · NA · recruiting
NCT06607432 — Temporal Interference Stimulation for Social Cognition · NA · recruiting

Other Max Planck Institute for Human Cognitive and Brain Sciences trials

Trials by the same sponsor.

NCT07501377 — Effects of a 6-months Fiber- and Polyphenol-rich Diet on Brain Inflammatory Processes in Perimenopausal Women Living Wit · NA · recruiting
NCT06116942 — Magnetic Brain Stimulation and Computer-based Motor Training for Rehabilitation After Stroke · NA · recruiting
NCT05232955 — Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 1: Simultaneous PET and 3T MRI · completed
NCT05233306 — Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 2: 7T MRI · completed
NCT03829189 — High-fiber Diet on the Body and the Brain · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03162185 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Max Planck Institute for Human Cognitive and Brain Sciences
Last refreshed: 22 May 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03162185.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing